Biota Holdings Limited (BTA)
Biota is an anti-infective drug development company, based in Melbourne, Australia. Since its initial public offering in 1985, Biota has evolved from a one program research company to a diversified drug discovery and development company with a portfolio of clinical and pre-clinical programs.
Biota receives royalties from two marketed products: Relenza™ (zanamivir) which is partnered globally with GSK; and Inavir® (laninamivir), a second generation influenza drug co-owned with Daiichi Sankyo and marketed by Daiichi Sankyo in Japan.
Key products in development comprise: laninamivir, which is being developed under a contract with BARDA in the US, which is intended to result in a new drug application to the FDA in 2016; vapendavir, which has completed Phase IIb studies designed to establish the effect of the drug on cold symptoms in asthmatics; and RSV, a preclinical, small molecule antiviral intended to provide prophylaxis and treatment of respiratory syncytial virus (RSV) infection.